FDA Approves Adcetris With Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma

The FDA has approved Adcetris in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation or CAR T-cell therapy.